Evidence map›Paper›PMID 18686744›Full record

SynthesisClinical interventions in aging2008

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Richard A Hansen, Gerald Gartlehner, Aaron P Webb, Laura C Morgan, Charity G Moore, Daniel E Jonas

Open access · greenAbstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Full text at PMC
In one paragraph

Synthesis in Clinical interventions in aging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 208 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
208citing papers in PubMed, 14 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

208 citing papers in PubMed, 14 syntheses or guidelines pooled it, 535 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Rivastigmine for vascular cognitive impairment.The Cochrane database of systematic reviews · 2013
    Pooled it
  12. Dementia.BMJ clinical evidence · 2012
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Efficacy and Safety ofNutrients · 2024
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

148 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Richard A HansenSchool of Pharmacy, Division of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. rahansen@unc.edu
Gerald Gartlehner
Aaron P Webb
Laura C Morgan
Charity G Moore
Daniel E Jonas
University of North Carolina at Chapel Hill · US

Funding

Multidisciplinary Clinical Research Career Develop(RMI)K12RR023248 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ORRINGER, EUGENE P · 2005 to 2007
$6.3M
NCRR NIH HHS K12 RR023248NCRR NIH HHS K12RR023248
6 · The paper itself

Abstract

Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine, and rivastigmine. We reviewed their evidence by searching MEDLINE, Embase, The Cochrane Library, and the International Pharmaceutical Abstracts from 1980 through 2007 (July) for placebo-controlled and comparative trials assessing cognition, function, behavior, global change, and safety. Thirty-three articles on 26 studies were included in the review. Meta-analyses of placebo-controlled data support the drugs' modest overall benefits for stabilizing or slowing decline in cognition, function, behavior, and clinical global change. Three open-label trials and one double-blind randomized trial directly compared donepezil with galantamine and rivastigmine. Results are conflicting; two studies suggest no differences in efficacy between compared drugs, while one study found donepezil to be more efficacious than galantamine, and one study found rivastigmine to be more efficacious than donepezil. Adjusted indirect comparison of placebo-controlled data did not find statistically significant differences among drugs with regard to cognition, but found the relative risk of global response to be better with donepezil and rivastigmine compared with galantamine (relative risk = 1.63 and 1.42, respectively). Indirect comparisons also favored donepezil over galantamine with regard to behavior. Across trials, the incidence of adverse events was generally lowest for donepezil and highest for rivastigmine.

Indexed as

Alzheimer DiseaseCholinesterase InhibitorsDonepezilGalantamineHumansIndansPhenylcarbamatesPiperidinesRivastigmineTreatment OutcomeCholinesterase InhibitorsDonepezilGalantamineIndansPhenylcarbamatesPiperidinesRivastigmine

Identifiers

PMID18686744
PMCPMC2546466
OpenAlexW38098989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.